Effect of Curodont™ Repair in Patients With Early Approximal Carious Lesions
Launched by CREDENTIS AG · Mar 28, 2014
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
All study participants must have two early approximal carious lesions in need of a treatment but not of an invasive treatment (split-mouth design). One lesion will be treated with Curodont Repair and one with fluoride as control. Study duration is 24 months. For assessment x-ray pictures, Diagnodent Pen and DiagnoCam is used.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Two approximal carious lesions on different teeth with at least one tooth in between
- • 2. Both study lesions must not require an invasive treatment
- • 3. Size and form of the lesions: the lesions must be fully visible and assessable on radiographs
- 4. The two carious lesions must fall into classes:
- • D2 (inner half of enamel)
- • D3 (outer part of dentine) but only if very little dentine is involved (enamel-dentine junction)
- • 5. Able and willing to observe good oral hygiene throughout the study
- • 6. Age ≥ 18 years and ≤ 65 years
- • 7. Willing and able to attend the on-study visits
- • 8. Willing and able to understand all study-related procedures
- • 9. Written informed consent before participation in the study
- Exclusion Criteria:
- • 1. The two study test lesions are located on adjacent teeth
- • 2. Fluoride varnish application \< 3 months prior to study treatment
- • 3. Tooth with numerous carious lesions
- • 4. Evidence of tooth erosion
- • 5. History of head and neck illnesses (e.g. head/neck cancer)
- • 6. Any pathology or concomitant medication affecting salivary flow or dry mouth
- • 7. Any metabolic disorders affecting bone turnover
- • 8. Patient suffers from diabetes
- • 9. Concurrent participation in another clinical trial
- • 10. Women who are breast-feeding, pregnant or who plan a pregnancy during the study
- • 11. Women of childbearing potential who declare being unwilling or unable to practice contraception such as hormonal contraceptives, sexual abstinence or intercourse with a vasectomised partner
About Credentis Ag
Credentis AG is a leading Swiss biotechnology company specializing in the development of innovative dental therapies and products. Focused on enhancing oral health, Credentis leverages cutting-edge technologies to create solutions that address unmet needs in dental care, including minimally invasive treatments and regenerative approaches. With a commitment to research and development, the company aims to improve patient outcomes and quality of life through its clinically validated products, demonstrating a strong dedication to advancing the field of dentistry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sirnach, Thurgau, Switzerland
Patients applied
Trial Officials
Mathias Seifert, Med. dent.
Principal Investigator
Zahnheilkunde Seifert Gmbh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials